Four-Year BIOMAG-I Study Results Confirm Safety of Freesolve Resorbable Magnesium Scaffold
The four-year follow-up data from the BIOMAG-I Clinical Study presented at EuroPCR shows that the Freesolve resorbable magnesium scaffold maintains a favorable long-term safety profile and sustained performance. Conducted across European centers with 116 patients, the study indicates no new cardiac events.
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the four‑year follow‑up data from the First-in-Human BIOMAG™-I Clinical Study (NCT04157153)* presented at the EuroPCR conference in Paris, France by Prof. Jan Torzewski (Klinikverbund Allgäu, Germany). Conducted exclusively across European centers and enrolling 116 patients, the study continues to demonstrate a favorable long‑term safety profile1, with no new cardia
